Skip to content

Turmeric in the treatment of recurrent aphthous stomatitis

Turmeric in the treatment of recurrent aphthous stomatitis: a double blind and placebo controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201107311556N28
Enrollment
50
Registered
2011-07-31
Start date
2011-07-31
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent aphthous stomatitis. Recurrent oral aphthae

Interventions

Intervention 1: Intervention group: Turmeric Jel (topical) three time a day by a swap. Intervention 2: Control group: Placebo gel, three time a day (topical) by a swap.
Treatment - Drugs
Placebo
Intervention group: Turmeric Jel (topical) three time a day by a swap
Control group: Placebo gel, three time a day (topical) by a swap

Sponsors

Erphan Teb
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 50 Patients between 20 and 45 years old will be included if they present with 1–5 aphthous ulcers of less than 24 h duration. The ulcers diameter will not be greater than 6 mm and they do not suffer from acute or chronic diseases of the oral mucosa Patients will be excluded from the study if they have concurrent clinical conditions including serious liver, kidney, and heart dysfunctions or if they have ulcers as a manifestation of a systemic disease process such as ulcerative colitis, Crohn’s disease, Behcet’s syndrome, or serious anaemia. To minimize the effect of confounding variables in the psycho- physiological component of the study, the patients should not have a history of alcohol or drug abuse and should not take any narcotic analgesics. Patients will be excluded if they have a history of systemic immunosuppressive therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Decrease of pain. Timepoint: Before treatment and days 2, 4, 6, 10 and 14 after treatment. Method of measurement: VAS rating scale.

Secondary

MeasureTime frame
Size of ulcers. Timepoint: Before drug application (day 0) and at days 2, 6, 10 and 14. Method of measurement: Diameters.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026